JP6111323B2 - 血液中の検体濃度を測定する方法および装置 - Google Patents
血液中の検体濃度を測定する方法および装置 Download PDFInfo
- Publication number
- JP6111323B2 JP6111323B2 JP2015506228A JP2015506228A JP6111323B2 JP 6111323 B2 JP6111323 B2 JP 6111323B2 JP 2015506228 A JP2015506228 A JP 2015506228A JP 2015506228 A JP2015506228 A JP 2015506228A JP 6111323 B2 JP6111323 B2 JP 6111323B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- time interval
- optical measurement
- variable
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims description 167
- 239000008280 blood Substances 0.000 title claims description 167
- 238000000034 method Methods 0.000 title claims description 154
- 239000012491 analyte Substances 0.000 title claims description 141
- 238000005259 measurement Methods 0.000 claims description 311
- 239000003153 chemical reaction reagent Substances 0.000 claims description 284
- 230000003287 optical effect Effects 0.000 claims description 282
- 238000012360 testing method Methods 0.000 claims description 240
- 238000001514 detection method Methods 0.000 claims description 135
- 230000008859 change Effects 0.000 claims description 122
- 238000005534 hematocrit Methods 0.000 claims description 111
- 238000012937 correction Methods 0.000 claims description 106
- 238000009736 wetting Methods 0.000 claims description 106
- 230000005764 inhibitory process Effects 0.000 claims description 98
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 82
- 239000008103 glucose Substances 0.000 claims description 82
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 238000000926 separation method Methods 0.000 claims description 54
- 238000011156 evaluation Methods 0.000 claims description 48
- 230000007704 transition Effects 0.000 claims description 41
- 230000004044 response Effects 0.000 claims description 37
- 239000000306 component Substances 0.000 claims description 33
- 239000012503 blood component Substances 0.000 claims description 32
- 230000002401 inhibitory effect Effects 0.000 claims description 31
- 230000003595 spectral effect Effects 0.000 claims description 14
- 230000002123 temporal effect Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 description 48
- 108090000790 Enzymes Proteins 0.000 description 48
- 229940088598 enzyme Drugs 0.000 description 48
- 239000005515 coenzyme Substances 0.000 description 43
- 239000010410 layer Substances 0.000 description 42
- 238000012545 processing Methods 0.000 description 38
- 238000002310 reflectometry Methods 0.000 description 31
- 230000006870 function Effects 0.000 description 27
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 26
- 238000013500 data storage Methods 0.000 description 24
- 230000000875 corresponding effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 15
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- -1 Vol. 10 Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 238000011049 filling Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229950006238 nadide Drugs 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000006399 behavior Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000005452 bending Methods 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 108010015776 Glucose oxidase Proteins 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical class NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000004065 semiconductor Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000005375 photometry Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020005199 Dehydrogenases Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- DGPLSUKWXXSBCU-VGXGLJSLSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1r,2r,3s,4r)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)C2)O)=C1 DGPLSUKWXXSBCU-VGXGLJSLSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 239000013039 cover film Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000007430 reference method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000008646 thermal stress Effects 0.000 description 3
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108030000198 L-amino-acid dehydrogenases Proteins 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 230000023077 detection of light stimulus Effects 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000853 optical rotatory dispersion Methods 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- ALNDFFUAQIVVPG-NGJCXOISSA-N (2r,3r,4r)-3,4,5-trihydroxy-2-methoxypentanal Chemical compound CO[C@@H](C=O)[C@H](O)[C@H](O)CO ALNDFFUAQIVVPG-NGJCXOISSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KCALAFIVPCAXJI-UHFFFAOYSA-N 1,10-phenanthroline-5,6-dione Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CN=C3C2=N1 KCALAFIVPCAXJI-UHFFFAOYSA-N 0.000 description 1
- JBLPWFLKCBTNBV-UHFFFAOYSA-N 1,7-phenanthroline-5,6-dione Chemical compound C1=CC=C2C(=O)C(=O)C3=NC=CC=C3C2=N1 JBLPWFLKCBTNBV-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 108010050201 2-hydroxybutyrate dehydrogenase Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-altritol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108700040097 Glycerol dehydrogenases Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- KNTVBBGVOSDILJ-UHFFFAOYSA-N [n-(hydroxymethyl)-4-nitrosoanilino]methanol;hydrochloride Chemical compound Cl.OCN(CO)C1=CC=C(N=O)C=C1 KNTVBBGVOSDILJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- FEYCFVFRMKWAOH-UHFFFAOYSA-N benzo[h]quinoline-2,3-dione Chemical compound C1=CC=C2C3=NC(=O)C(=O)C=C3C=CC2=C1 FEYCFVFRMKWAOH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000001369 canonical nucleoside group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000007562 laser obscuration time method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- KOOMFXGDLMRWSN-UHFFFAOYSA-N n-phenylnitrous amide Chemical class O=NNC1=CC=CC=C1 KOOMFXGDLMRWSN-UHFFFAOYSA-N 0.000 description 1
- 238000007649 pad printing Methods 0.000 description 1
- 238000012567 pattern recognition method Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- VLPADTBFADIFKG-UHFFFAOYSA-N phanquone Chemical compound C1=CN=C2C(=O)C(=O)C3=NC=CC=C3C2=C1 VLPADTBFADIFKG-UHFFFAOYSA-N 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
- G01N21/272—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration for following a reaction, e.g. for determining photometrically a reaction rate (photometric cinetic analysis)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/8483—Investigating reagent band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12164805 | 2012-04-19 | ||
| EP12164805.9 | 2012-04-19 | ||
| PCT/EP2013/057999 WO2013156526A1 (de) | 2012-04-19 | 2013-04-17 | Verfahren und vorrichtung zur bestimmung einer analytkonzentration in blut |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514987A JP2015514987A (ja) | 2015-05-21 |
| JP2015514987A5 JP2015514987A5 (enExample) | 2016-03-17 |
| JP6111323B2 true JP6111323B2 (ja) | 2017-04-05 |
Family
ID=48095890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506228A Active JP6111323B2 (ja) | 2012-04-19 | 2013-04-17 | 血液中の検体濃度を測定する方法および装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9599552B2 (enExample) |
| EP (1) | EP2839267B1 (enExample) |
| JP (1) | JP6111323B2 (enExample) |
| KR (1) | KR101728597B1 (enExample) |
| CN (1) | CN104246482B (enExample) |
| CA (1) | CA2865678C (enExample) |
| WO (1) | WO2013156526A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103154336B (zh) * | 2010-10-13 | 2015-08-12 | 三菱丽阳株式会社 | 碳纤维前体纤维束、碳纤维束以及它们的用途 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
| US20060281187A1 (en) | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
| JP5232003B2 (ja) | 2005-09-30 | 2013-07-10 | インテュイティ メディカル インコーポレイテッド | 多部分体液試料採取及び分析カートリッジ |
| US8801631B2 (en) | 2005-09-30 | 2014-08-12 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
| WO2009145920A1 (en) | 2008-05-30 | 2009-12-03 | Intuity Medical, Inc. | Body fluid sampling device -- sampling site interface |
| US10383556B2 (en) | 2008-06-06 | 2019-08-20 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
| JP5642066B2 (ja) | 2008-06-06 | 2014-12-17 | インテュイティ メディカル インコーポレイテッド | 体液の試料内に含まれている検体の存在または濃度を決定する検定を行う方法および装置 |
| EP3106871B1 (en) | 2009-11-30 | 2021-10-27 | Intuity Medical, Inc. | A method of verifying the accuracy of the operation of an analyte monitoring device |
| EP2584964B1 (en) | 2010-06-25 | 2021-08-04 | Intuity Medical, Inc. | Analyte monitoring devices |
| EP3750480B1 (en) | 2011-08-03 | 2022-02-02 | Intuity Medical, Inc. | Body fluid sampling arrangement |
| US10729386B2 (en) | 2013-06-21 | 2020-08-04 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
| US10417076B2 (en) | 2014-12-01 | 2019-09-17 | Uptake Technologies, Inc. | Asset health score |
| GB201507509D0 (en) * | 2015-04-30 | 2015-06-17 | Inside Biometrics Ltd | Electrochemical Test Device |
| US9836839B2 (en) * | 2015-05-28 | 2017-12-05 | Tokitae Llc | Image analysis systems and related methods |
| CN105021538A (zh) * | 2015-08-13 | 2015-11-04 | 武汉华乙电气自动化科技有限公司 | 一种水体泥沙含量检测系统 |
| EP3150996A1 (en) * | 2015-10-02 | 2017-04-05 | Hach Company | Apparatus and method for determining a water hardness value |
| WO2017191118A1 (en) * | 2016-05-03 | 2017-11-09 | Ventana Medical Systems, Inc. | System and method for monitoring reagent concentrations |
| CN111448449B (zh) * | 2017-02-16 | 2024-08-27 | 上海宜晟生物科技有限公司 | 采用纹理化表面的测定方法及装置 |
| JP7029903B2 (ja) * | 2017-08-09 | 2022-03-04 | シスメックス株式会社 | 試料処理装置、試料処理システム、および測定時間の算出方法 |
| CN107643263B (zh) * | 2017-08-31 | 2021-01-26 | 上海市第一康复医院(上海市杨浦区老年医院) | 基于光梳相干成像分析的生物分子检测方法 |
| KR102615999B1 (ko) * | 2017-10-19 | 2023-12-22 | 한국전자통신연구원 | 혈액분석장치 |
| KR20190076624A (ko) * | 2017-12-22 | 2019-07-02 | 삼성전자주식회사 | 검사 장치 및 그 제어방법 |
| CN109142252A (zh) * | 2018-09-29 | 2019-01-04 | 重庆迈联医疗科技有限公司 | 一种模块化的血脂检测仪 |
| PT3650843T (pt) * | 2018-11-07 | 2022-03-11 | Hoffmann La Roche | Métodos e dispositivos para realizar uma medição analítica |
| CN111198182A (zh) * | 2018-11-20 | 2020-05-26 | 苏州迈瑞科技有限公司 | 一种干化学检测方法和装置 |
| RU2768216C1 (ru) | 2018-11-30 | 2022-03-23 | Ф. Хоффманн-Ля Рош Аг | Способ определения концентрации аналита в физиологической жидкости |
| CN110575182A (zh) * | 2019-08-30 | 2019-12-17 | 北京信息科技大学 | 用于检测血糖的方法及装置 |
| CN117074666B (zh) * | 2023-08-18 | 2024-10-01 | 杭州宣航科技有限公司 | 试纸条阴阳性识别方法、装置、电子设备及存储介质 |
| CN121207866A (zh) * | 2025-10-10 | 2025-12-26 | 三诺生物传感股份有限公司 | 一种分析物的光学检测方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4178153A (en) * | 1977-11-21 | 1979-12-11 | Damon Corporation | Method and apparatus for chemical spot test analysis |
| JPS62206432A (ja) * | 1986-03-06 | 1987-09-10 | Fuji Photo Film Co Ltd | 酵素活性の定量方法 |
| US5049487A (en) | 1986-08-13 | 1991-09-17 | Lifescan, Inc. | Automated initiation of timing of reflectance readings |
| US4935346A (en) | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
| IL85778A0 (en) | 1987-03-20 | 1988-09-30 | Bristol Myers Co | Production of 2',3'-dideoxynucleosides and certain such novel compounds |
| DE3725766A1 (de) | 1987-08-04 | 1989-02-16 | Boehringer Mannheim Gmbh | Testtraeger zur bestimmung eines analyten aus blut und verfahren zu seiner herstellung |
| DE3826922A1 (de) | 1988-08-09 | 1990-02-22 | Boehringer Mannheim Gmbh | Verfahren zur kolorimetrischen bestimmung eines analyten mittels enzymatischer oxidation |
| JP2618727B2 (ja) * | 1990-01-19 | 1997-06-11 | 富士写真フイルム株式会社 | 全血中の被検成分の定量方法 |
| US5246858A (en) * | 1991-02-27 | 1993-09-21 | Boehringer Mannheim Corporation | Apparatus and method for analyzing a body fluid |
| TW227042B (enExample) | 1991-12-19 | 1994-07-21 | Eastman Kodak Co | |
| IL120587A (en) * | 1996-04-04 | 2000-10-31 | Lifescan Inc | Reagent test strip for determination of blood glucose |
| DE19629656A1 (de) | 1996-07-23 | 1998-01-29 | Boehringer Mannheim Gmbh | Diagnostischer Testträger mit mehrschichtigem Testfeld und Verfahren zur Bestimmung von Analyt mit dessen Hilfe |
| JP3618210B2 (ja) * | 1997-03-19 | 2005-02-09 | テルモ株式会社 | 成分測定装置 |
| DE19753850A1 (de) | 1997-12-04 | 1999-06-10 | Roche Diagnostics Gmbh | Probennahmevorrichtung |
| DE19753847A1 (de) | 1997-12-04 | 1999-06-10 | Roche Diagnostics Gmbh | Analytisches Testelement mit Kapillarkanal |
| DE19753851A1 (de) | 1997-12-04 | 1999-06-10 | Roche Diagnostics Gmbh | Vorrichtung zum kapillaren Flüssigkeitstransport |
| DE19912365A1 (de) | 1999-03-19 | 2000-09-21 | Roche Diagnostics Gmbh | Mehrschichtiges analytisches Hilfsmittel |
| ATE345396T1 (de) | 2002-05-16 | 2006-12-15 | Hoffmann La Roche | Verfahren zur herstellung von polymerschichten |
| JP4299597B2 (ja) * | 2002-07-29 | 2009-07-22 | シスメックス株式会社 | 血液分析装置及び方法 |
| US20080003141A1 (en) * | 2004-04-30 | 2008-01-03 | Kazuya Iketani | Sample Analyzing Tool |
| AU2005201576B2 (en) | 2004-05-07 | 2010-06-24 | F. Hoffmann-La Roche Ag | Process and device for producing an analytical tape for liquid samples |
| CA2577688A1 (en) | 2004-08-24 | 2006-03-02 | Bayer Healthcare Llc | Method for determining the concentration of analytes in samples by direct mediation of enzymes |
| US20060281187A1 (en) | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
| JP4786451B2 (ja) | 2005-07-28 | 2011-10-05 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | Ｎａｄ／ｎａｄｈの安定化 |
| DE102005035461A1 (de) | 2005-07-28 | 2007-02-15 | Roche Diagnostics Gmbh | Stabile NAD/NADH-Derivate |
| JP4041826B2 (ja) * | 2005-08-11 | 2008-02-06 | テルモ株式会社 | 血液検査測定器および測定値補正方法 |
| JP2007101482A (ja) | 2005-10-07 | 2007-04-19 | Matsushita Electric Ind Co Ltd | 測定チップならびにその分析方法 |
| PL3246402T3 (pl) | 2006-04-13 | 2020-10-19 | F. Hoffmann-La Roche Ag | Ulepszone mutanty rozpuszczalnej dehydrogenazy glukozowej zależnej od pirolochinolinochinonu |
| JP4785611B2 (ja) | 2006-05-11 | 2011-10-05 | アークレイ株式会社 | 血液試料中の特定成分の濃度測定方法および装置 |
| GB0705495D0 (en) * | 2007-03-22 | 2007-05-02 | Quotient Diagnostics Ltd | Whole blood assay |
| US8080153B2 (en) | 2007-05-31 | 2011-12-20 | Abbott Diabetes Care Inc. | Analyte determination methods and devices |
| JP5427362B2 (ja) | 2008-03-25 | 2014-02-26 | テルモ株式会社 | ヘマトクリット値または血液成分濃度の測定方法および測定装置 |
| JP2009233253A (ja) * | 2008-03-28 | 2009-10-15 | Terumo Corp | 血糖測定装置および血糖測定方法 |
| KR101311020B1 (ko) | 2008-11-07 | 2013-09-25 | 에프. 호프만-라 로슈 아게 | 광도계 반응 필름용 세립 충전물질 |
| EP2226008A1 (de) | 2009-02-19 | 2010-09-08 | Roche Diagnostics GmbH | Verfahren zur Herstellung eines analytischen Magazins |
| CN102325496B (zh) | 2009-02-19 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 分析辅助工具的节省空间的储存 |
| US8095734B2 (en) * | 2009-04-30 | 2012-01-10 | Lsi Corporation | Managing cache line allocations for multiple issue processors |
| JP4664425B2 (ja) | 2009-06-05 | 2011-04-06 | 株式会社日立製作所 | 多層光ディスクの記録方法 |
| EP2325624A1 (de) * | 2009-11-18 | 2011-05-25 | F. Hoffmann-La Roche AG | Verfahren und Vorrichtung zur Untersuchung einer Körperflüssigkeit |
| US8391940B2 (en) * | 2010-02-04 | 2013-03-05 | Lifescan, Inc. | Methods and systems to correct for hematocrit effects |
| KR20150079965A (ko) * | 2012-12-04 | 2015-07-08 | 에프. 호프만-라 로슈 아게 | 헤마토크리트 정정을 위한 방법 및 그 방법을 위해 구성된 글루코스 측정기 |
| EP2936155B1 (en) * | 2012-12-20 | 2018-12-12 | Roche Diabetes Care GmbH | Method for analyzing a sample of a body fluid |
-
2013
- 2013-04-17 JP JP2015506228A patent/JP6111323B2/ja active Active
- 2013-04-17 WO PCT/EP2013/057999 patent/WO2013156526A1/de not_active Ceased
- 2013-04-17 CN CN201380020601.2A patent/CN104246482B/zh active Active
- 2013-04-17 CA CA2865678A patent/CA2865678C/en active Active
- 2013-04-17 EP EP13716323.4A patent/EP2839267B1/de active Active
- 2013-04-17 KR KR1020147029202A patent/KR101728597B1/ko active Active
-
2014
- 2014-10-17 US US14/516,653 patent/US9599552B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103154336B (zh) * | 2010-10-13 | 2015-08-12 | 三菱丽阳株式会社 | 碳纤维前体纤维束、碳纤维束以及它们的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865678A1 (en) | 2013-10-24 |
| CN104246482B (zh) | 2017-04-12 |
| US20150037898A1 (en) | 2015-02-05 |
| KR101728597B1 (ko) | 2017-04-19 |
| HK1205260A1 (en) | 2015-12-11 |
| KR20140134334A (ko) | 2014-11-21 |
| US9599552B2 (en) | 2017-03-21 |
| JP2015514987A (ja) | 2015-05-21 |
| EP2839267A1 (de) | 2015-02-25 |
| CA2865678C (en) | 2018-03-13 |
| CN104246482A (zh) | 2014-12-24 |
| WO2013156526A1 (de) | 2013-10-24 |
| EP2839267B1 (de) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514987A (ja) | 血液中の検体濃度を測定する方法および装置 | |
| JP6059244B2 (ja) | 試料中の少なくとも１つの分析物を検出するための分析装置 | |
| JP6518289B2 (ja) | 分析物濃度を決定するための方法 | |
| JPWO2018061484A1 (ja) | 血液サンプル中の分析対象物を検出するための、方法、組成物およびチップ | |
| JP5427362B2 (ja) | ヘマトクリット値または血液成分濃度の測定方法および測定装置 | |
| KR101506928B1 (ko) | 보호된 분석대상물의 제어 방출에 의한 시험 요소에서 효소의 분해 검출 | |
| HK1205260B (en) | Method and device for determining an analyte concentration in blood | |
| EP2807270B1 (en) | Method for the evaluation of the quality of a test element | |
| HK1200681B (en) | Analytical apparatus for detecting at least one analyte in a sample | |
| HK1201074B (en) | Method for determining an analyte concentration | |
| HK1132643B (en) | Abnormal output detection system for a biosensor | |
| HK1132643A1 (en) | Abnormal output detection system for a biosensor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160720 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161014 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170228 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170313 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6111323 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |